SNY•benzinga•
Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition
Summary
Sanofi (SNY) to acquire Vigil Neuroscience (VIGL) for $470 million in cash, plus potential $2 per share payout. Acquisition excludes monoclonal antibody program and is expected to be finalized in Q3 2025. VG-3927 showed promise in Phase 1 for Alzheimer's treatment.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 22, 2025 by benzinga